2018
Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing
Giri V, Hegarty S, Hyatt C, O'Leary E, Garcia J, Knudsen K, Kelly W, Gomella L. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. The Prostate 2018, 79: 333-339. PMID: 30450585, DOI: 10.1002/pros.23739.Peer-Reviewed Original ResearchConceptsBreast cancer family historyCancer family historyProstate cancerFamily historyMetastatic diseaseGleason scoreExact testGenetic testingRetrospective cross-sectional analysisDNA repair genesCurrent NCCN guidelinesInherited prostate cancerGermline genetic testingHigh Gleason scoreFisher's exact testIdentification of menRepair genesPathogenic variant spectrumCross-sectional analysisFamily history dataGenetic testing capabilitiesNCCN guidelinesTherapeutic managementMultigene testingPV rates
2014
Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.
Carroll P, Parsons J, Andriole G, Bahnson R, Barocas D, Catalona W, Dahl D, Davis J, Epstein J, Etzioni R, Giri V, Hemstreet G, Kawachi M, Lange P, Loughlin K, Lowrance W, Maroni P, Mohler J, Morgan T, Nadler R, Poch M, Scales C, Shanefelt T, Vickers A, Wake R, Shead D, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. Journal Of The National Comprehensive Cancer Network 2014, 12: 1211-9; quiz 1219. PMID: 25190691, DOI: 10.6004/jnccn.2014.0120.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProstate cancer early detectionCancer early detectionNCCN guidelinesProstate cancerEarly detectionNCCN Guidelines InsightsNotable recent updatesProstate Health IndexEarly Detection ProgramRecent FDA approvalMultiple risk variablesBiopsy decisionsFDA approvalDetection programRisk variablesCancerHealth indexRecent updatesMenGuidelinesBiopsy